Expert Panel Timelines: What Actually Delays Your Certification
Most manufacturers discover their certification path needs an expert panel consultation only after the Notified Body raises the question. By then, the timeline is already compressed. The consultation itself takes time, but the real delays happen before the panel even sees your file.
In This Article
- Where the Delay Actually Starts
- What the Notified Body Looks for Before Triggering the Panel
- The Hidden Timeline Between Submission and Consultation
- What Happens During the 60 Days
- What Delays You Cannot Avoid and What You Can
- How to Prepare for the Expert Panel Before You Submit
- What Happens After the Panel Opinion
Under MDR Article 106, certain devices require a consultation with an expert panel before a Notified Body can grant certification. This applies primarily to implantable devices and Class III devices without a well-established equivalent already on the market. The consultation is not optional. It is built into the conformity assessment pathway.
The regulation sets a theoretical timeline: the expert panel has 60 days to deliver an opinion after receiving the documentation. In urgent cases involving public health, this can be shortened to 30 days. On paper, this sounds manageable.
In practice, the 60 days are rarely the issue.
Where the Delay Actually Starts
The expert panel consultation does not start when you submit your technical file to the Notified Body. It starts when the Notified Body determines that your file is complete enough to forward to the panel.
This is the first inflection point most manufacturers miss.
The Notified Body will review your clinical evaluation report, PMCF plan, risk management file, and device description before deciding to trigger the consultation. If they find gaps, inconsistencies, or incomplete justifications, they will not forward the file. Instead, they will issue questions or deficiencies.
You respond. They review again. Another round of questions. Another response. Weeks pass.
The clinical evaluation report describes the device and its intended use, but does not adequately justify why equivalence cannot be established or why the device represents a sufficiently novel approach to require panel consultation. The Notified Body cannot proceed without this clarity.
The Notified Body is acting as a filter. They will not waste the expert panel’s time with a file that is not defensible. Their role is to ensure that when the panel receives the submission, it is clear, complete, and ready for scientific assessment.
This is not obstructionism. It is risk management. If the panel returns a negative opinion or raises fundamental questions, the Notified Body must address them or halt the process. They prefer to catch issues early.
What the Notified Body Looks for Before Triggering the Panel
The Notified Body will assess whether your clinical evaluation is solid enough to withstand expert scrutiny. They look at the quality of the literature search, the appraisal of clinical data, the handling of safety signals, and the coherence of your benefit-risk conclusion.
They also check whether your PMCF plan is credible. The expert panel will want to know how post-market data will address residual uncertainties. If your PMCF plan is vague or lacks clear endpoints, the Notified Body will flag it.
They verify that your risk management file is consistent with your clinical evaluation. If the clinical evaluation describes low residual risk but the risk file lists unmitigated concerns, the panel will notice. The Notified Body will ask you to resolve this before submission.
Finally, they confirm that your device description and technical documentation align with what the clinical evaluation discusses. If the intended use in the clinical evaluation differs from the IFU, the panel cannot assess coherence.
The Notified Body does not just check boxes. They assess whether your file can survive expert panel review. Every question they ask before submission is a question the panel would have asked later, with more serious consequences.
The Hidden Timeline Between Submission and Consultation
Even after the Notified Body decides to forward your file, there is a coordination step. The panel consultation is managed by the competent authorities, not by the Notified Body. The file must be submitted through the official channels. The panel members must be available. The documentation must be formatted and anonymized according to the process defined in MDCG 2020-13.
This administrative layer adds time. It is not included in the 60-day clock.
The 60 days start only when the expert panel formally acknowledges receipt and begins its review. Before that point, several working days or weeks may pass while the submission is prepared, validated, and assigned to panel members.
You cannot control this part of the timeline. But you can control whether the Notified Body decides to forward your file without delays.
What Happens During the 60 Days
Once the expert panel begins its review, the clock runs. The panel assesses the clinical evidence, the benefit-risk profile, and the adequacy of your PMCF strategy. They may request additional information or clarification from the Notified Body.
If they ask questions, the Notified Body forwards them to you. You respond. The Notified Body reviews your response and sends it back to the panel. This back-and-forth happens within the 60-day window, but it compresses the time available for the panel’s final deliberation.
The panel’s opinion can be positive, positive with conditions, or negative. A positive opinion allows the Notified Body to continue the certification process. A conditional opinion means you must address specific requirements before certification can proceed. A negative opinion stops the process entirely.
The conditions or objections raised by the panel are not suggestions. They are binding. You must address them before the Notified Body can issue a certificate.
Manufacturers assume that a conditional opinion only requires minor adjustments. In practice, conditional opinions often require substantial updates to the clinical evaluation, additional clinical data, or redesign of the PMCF plan. These changes take months, not weeks.
What Delays You Cannot Avoid and What You Can
You cannot speed up the 60-day panel review. You cannot control the administrative handoff between the Notified Body and the competent authority. You cannot influence the panel’s internal deliberations or availability.
But you can ensure that the Notified Body forwards your file on the first attempt. You can avoid the cycle of questions and resubmissions that extends your timeline by months. You can make sure that when the panel sees your file, it is clear enough that they do not need to ask clarifying questions.
The difference between a certification delayed by months and one that proceeds smoothly often comes down to the quality of preparation before the expert panel even gets involved.
How to Prepare for the Expert Panel Before You Submit
Start by understanding whether your device will require an expert panel consultation. If you are designing a Class III device or an implantable device without clear equivalence to an existing device, assume the panel will be involved. Do not wait for the Notified Body to tell you.
Build your clinical evaluation with the panel review in mind. This means being explicit about why the device is novel, what clinical uncertainties remain, and how your PMCF plan will address them. The panel is composed of clinicians and scientists. They will look for scientific rigor, not regulatory compliance language.
Align your technical documentation with your clinical evaluation before submission. Make sure the device description, intended use, risk analysis, and clinical data tell the same story. Inconsistencies will trigger questions from both the Notified Body and the panel.
Work with your Notified Body early. Share your clinical evaluation strategy and ask whether they see gaps that would delay the expert panel submission. This is not about getting approval in advance. It is about understanding their assessment criteria so you can prepare accordingly.
The expert panel consultation is not a separate regulatory step. It is the endpoint of a chain of assessments that starts with your clinical evaluation. If you optimize for the panel from the beginning, you reduce delays throughout the entire process.
What Happens After the Panel Opinion
Once the expert panel issues its opinion, the Notified Body incorporates it into their conformity assessment. If the opinion is positive, the certification process continues. If conditions were set, you must demonstrate compliance before the Notified Body proceeds.
The panel opinion is documented and becomes part of your technical file. If you make significant changes to the device or its clinical evaluation later, the Notified Body may decide that a new panel consultation is required. This is why it is critical to get it right the first time.
The expert panel process is not designed to create delays. It is designed to ensure that high-risk devices entering the market have sufficient clinical evidence and post-market follow-up. The delays happen when manufacturers treat the panel consultation as an afterthought rather than as a central element of their certification strategy.
The timeline is predictable if you prepare correctly. The uncertainty comes from reactive submission strategies that assume the Notified Body and the panel will accept documentation that was not designed for their level of scrutiny.
If your certification timeline extends by six months, it is rarely because the panel took too long. It is because the file was not ready when it was first submitted.
Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report). MDR Article 106, MDCG 2020-13
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
– MDR 2017/745 Article 106
– MDCG 2020-13 on Clinical Evaluation Assessment
Deepen Your Knowledge
Read Complete Guide to Clinical Evaluation under EU MDR for a comprehensive overview of clinical evaluation under EU MDR 2017/745.
